IPO - Profile


We believe that we are a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Our synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of our solution is our BioXp system, an More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$$16.00 6,670,000 Positive High 55.58%

Offering Team

  • Legal counsel
  • Wilson Sonsini Goodrich & Rosati, P.C
  • Auditors
  • OUM & CO. LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 17 Jun, 2021

Offer 18 Jun, 2021

Look Ahead

Lock Up Expiry Dec 18, 2021

IPO Terms

Offer Price $$16.00
Offer Size 6M

Market Sentiments

Stock Price